Clinical Trials: Search Results

Your search returned 20 results.

 
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
Conditions:
Prostate Cancer; Benign Prostatic Hyperplasia; Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)

Intervention:
Drug: BOTOX;
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
Conditions:
Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Intervention:
Radiation: intensity modulated external beam radiation therapy;
Korean Practice Patterns for Screening PCA(Prostate Cancer)
Conditions:
Neoplasms, Prostate; Prostate Cancer; Benign Prostatic Hyperplasia

Intervention:
Other: continuous screening;
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Conditions:
Prostate Cancer; Prostatic Cancer; Prostate Neoplasms; Prostatic Neoplasms; Cancer of the Prostate

Intervention:
Radiation: CyberKnife Stereotactic Radiosurgery;
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Conditions:
Prostate Cancer; Prostatic Cancer; Prostatic Neoplasms; Prostate Neoplasms; Cancer of the Prostate

Intervention:
Radiation: CyberKnife Stereotactic Radiosurgery;
Lyophilized Black Raspberry in Treating Patients With Prostate Cancer Undergoing Surgery
Conditions:
Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Intervention:
Drug: lyophilized black raspberry lozenge; Other: laboratory biomarker analysis; Dietary Supplement: dietary intervention; Dietary Supplement: dietary intervention; Procedure: therapeutic conventional surgery; Procedure: quality-of-life assessment; Other: questionnaire administration;
Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer
Conditions:
Adenocarcinoma of the Prostate; Castration-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Intervention:
Drug: cabozantinib-s-malate; Other: laboratory biomarker analysis;
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate
Conditions:
Prostate Cancer; Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer

Intervention:
Drug: Docetaxel; Drug: Prednisone;
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
Conditions:
Stage IV Prostate Cancer; Bone Metastases; Adenocarcinoma of the Prostate; Recurrent Prostate Cancer

Intervention:
Drug: alendronate sodium; Drug: ketoconazole;
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
Conditions:
Stage IV Prostate Cancer; Adenocarcinoma of the Prostate; Recurrent Prostate Cancer

Intervention:
Drug: docetaxel; Drug: thalidomide;
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions:
Metastatic Prostate Cancer; Cancer of the Prostate; Prostate Cancer

Intervention:
Drug: Anti-OX40; Radiation: Radiation; Drug: Cyclophosphamide;
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Conditions:
Clinical Stage T2b or Less of Prostate Cancer; Prostate Brachytherapy; Transrectal Prostate Ultrasound Treatment Planning

Intervention:
Other: An ultrasound-based technique to identify prostate cancer; Other: pre-implant transrectal ultrasound images and planning; Other: ultrasound-based cancer-specific images;
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
Conditions:
Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer

Intervention:
Biological: recombinant fowlpox-prostate specific antigen vaccine; Biological: recombinant vaccinia prostate-specific antigen vaccine; Other: laboratory biomarker analysis;
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Conditions:
Prostate Cancer; Benign Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia

Intervention:
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Conditions:
Castrate Resistant Prostate Cancer; Chemotherapy Naive Prostate Cancer; Prostate Cancer

Intervention:
Drug: Pasireotide; Drug: Everolimus; Other: Laboratory biomarker analysis;
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
Conditions:
Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer

Intervention:
Dietary Supplement: defined green tea catechin extract; Drug: placebo; Other: immunohistochemistry staining method; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: biopsy; Other: mass spectrometry; Other: high performance liquid chromatography;
Genistein in Treating Patients With Prostate Cancer
Conditions:
Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer

Intervention:
Dietary Supplement: genistein; Other: placebo; Procedure: therapeutic conventional surgery;
High-Dose Stereotactic Radiation for Prostate Cancer
Conditions:
Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer

Intervention:
Radiation: stereotactic body radiation therapy; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis;
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Conditions:
Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer

Intervention:
Drug: metformin hydrochloride; Other: placebo; Other: laboratory biomarker analysis;
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Conditions:
Small Cell Prostate Cancer; Neuroendocrine Prostate Cancer; Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

Intervention:
Drug: MLN8237;